Trametinib in Treating Patients With Advanced Cancer With or Without Hepatic Dysfunction
NCT ID: NCT02070549
Last Updated: 2025-02-13
Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
COMPLETED
Clinical Phase
PHASE1
Total Enrollment
46 participants
Study Classification
INTERVENTIONAL
Study Start Date
2014-03-10
Study Completion Date
2024-12-18
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
This phase I trial studies the side effects and best dose of trametinib in treating patients with cancer that has spread to other places in the body and usually cannot be cured or controlled with treatment (advanced) with or without liver (hepatic) dysfunction. Trametinib may stop the growth of tumor cells by blocking proteins needed for cell growth. When these proteins are blocked, the growth of cancer cells may be stopped and the cancer cells will then die. Hepatic dysfunction is frequently found in patients with advanced cancer and usually prevents patients from receiving standard treatments or from participating in clinical trials. Patients may also need dose adjustments or absorb drugs differently. Trametinib may be a better treatment for patients with advanced cancers and hepatic dysfunction.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Sorafenib in Treating Patients With Metastatic or Unresectable Solid Tumors, Multiple Myeloma, or Non-Hodgkin's Lymphoma With or Without Impaired Liver or Kidney Function
NCT00118170
Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue
Nodal Marginal Zone B-cell Lymphoma
Recurrent Adult Burkitt Lymphoma
+42 more
COMPLETED
PHASE1
TRC105 for Liver Cancer That Has Not Responded to Sorafenib
NCT01375569
Hepatocellular Carcinoma
Hepatocellular Cancer
Carcinoma, Hepatocellular
COMPLETED
PHASE2
Trametinib in Treating Patients With Epithelioid Hemangioendothelioma That is Metastatic, Locally Advanced, or Cannot Be Removed by Surgery
NCT03148275
Locally Advanced Epithelioid Hemangioendothelioma
Metastatic Epithelioid Hemangioendothelioma
Unresectable Epithelioid Hemangioendothelioma
COMPLETED
PHASE2
A Study to Determine the Relative Bioavailability of the MEK Inhibitor, Trametinib, in Subjects With Solid Tumor Malignancies
NCT01725100
Cancer
COMPLETED
PHASE1
Temsirolimus in Treating Patients With Metastatic Solid Tumor or Lymphoma That Cannot Be Removed By Surgery Who Have Different Levels of Liver Function
NCT00275093
Hepatic Complications
Lymphoma
Unspecified Adult Solid Tumor, Protocol Specific
COMPLETED
PHASE1
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
PRIMARY OBJECTIVES:
I. To provide appropriate dosing recommendations for patients with varying degree of hepatic dysfunction receiving trametinib (mild, moderate and severe).
II. To establish the maximum tolerated dose (MTD) and dose-limiting toxicity (DLT) of trametinib in advanced cancer patients with varying degrees of hepatic dysfunction.
III. To characterize the pharmacokinetic (PK) profile of trametinib in advanced cancer patients with varying degrees of hepatic dysfunction.
SECONDARY OBJECTIVES:
I. To document the non-DLTs associated with the administration of trametinib in patients with varying degrees of hepatic dysfunction.
II. To document any antitumor activity associated with trametinib treatment of patients enrolled on this study.
III. To explore and characterize predictive biomarkers for individual cancer patients utilizing genomic sequencing technologies.
OUTLINE: This is a dose-escalation study.
Patients receive trametinib orally (PO) once daily (QD) on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
After completion of study treatment, patients are followed up for 4 weeks.
I. To provide appropriate dosing recommendations for patients with varying degree of hepatic dysfunction receiving trametinib (mild, moderate and severe).
II. To establish the maximum tolerated dose (MTD) and dose-limiting toxicity (DLT) of trametinib in advanced cancer patients with varying degrees of hepatic dysfunction.
III. To characterize the pharmacokinetic (PK) profile of trametinib in advanced cancer patients with varying degrees of hepatic dysfunction.
SECONDARY OBJECTIVES:
I. To document the non-DLTs associated with the administration of trametinib in patients with varying degrees of hepatic dysfunction.
II. To document any antitumor activity associated with trametinib treatment of patients enrolled on this study.
III. To explore and characterize predictive biomarkers for individual cancer patients utilizing genomic sequencing technologies.
OUTLINE: This is a dose-escalation study.
Patients receive trametinib orally (PO) once daily (QD) on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
After completion of study treatment, patients are followed up for 4 weeks.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Advanced Malignant Solid Neoplasm
Metastatic Malignant Neoplasm in the Liver
Metastatic Malignant Solid Neoplasm
Unresectable Solid Neoplasm
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Allocation Method
NA
Intervention Model
SINGLE_GROUP
Primary Study Purpose
TREATMENT
Blinding Strategy
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Treatment (trametinib)
Patients receive trametinib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
Group Type
EXPERIMENTAL
Trametinib
Intervention Type
DRUG
Given PO
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Trametinib
Given PO
Intervention Type
DRUG
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
GSK 1120212
GSK 212
GSK-1120212
GSK-212
GSK1120212
GSK212
JTP 74057
JTP-74057
JTP74057
MEK Inhibitor GSK1120212
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patients must have a histologically or cytologically confirmed solid malignancy that is metastatic or unresectable for which standard curative or palliative treatments do not exist or are no longer effective
* Hepatocellular carcinoma (HCC) patients are not required to have histologically or cytologically confirmed malignancy, patients are considered eligible based on tumor markers and/or imaging assessment
* Based on recent data that have shown limited trametinib benefit, patients with the following tumor types will be excluded from the normal and mild cohorts:
* Pancreatic cancer patients
* Colorectal cancer patients
* BRAF V600E melanoma patients who have failed BRAF inhibitors
* Note: Patients with pancreatic cancer, colorectal cancer, and BRAF V600E melanoma patients who have failed BRAF inhibitors are allowed to enroll in the moderate and severe cohorts provided the patients: 1) sign a separate consent form which outlines the extremely limited activity observed in prior studies, and 2) are consented to the study by a protocol-specified designee who is not their longitudinal oncologist
* All patients must have completed any prior chemotherapy, targeted therapy, radiotherapy (unless palliative doses which must be discussed with study principal investigator), surgery, anti-angiogenic therapy or interferon \>= 28 days before study entry
* Eastern Cooperative Oncology Group (ECOG) performance status =\< 2 (Karnofsky \>= 60%)
* Life expectancy of greater than 3 months
* Able to swallow and retain orally-administered medication and does not have any clinically significant gastrointestinal abnormalities that may alter absorption such as malabsorption syndrome or major resection of the stomach or bowels
* All prior treatment-related toxicities must be Common Terminology Criteria for Adverse Events (CTCAE) version 4.0 grade =\< 1 (except alopecia) at the time of enrollment
* Absolute neutrophil count (ANC) \>= 1.2 x 10\^9/L
* Hemoglobin \>= 9 g/dL
* Platelets \>= 75 x 10\^9/L
* Serum creatinine =\< 1.5 mg/dL (=\< 133 umol/L) OR calculated creatinine clearance (Cockcroft-Gault formula) \>= 50 mL/min OR 24-hour urine creatinine clearance \>= 50 mL/min
* Proteinuria =\< +1 on dipstick or =\< 1 gram/24 hours
* Prothrombin time (PT) =\< 1.5 x institutional upper limit of normal (ULN)
* International normalized ratio (INR) =\< 1.5 x institutional ULN
* Partial thromboplastin time (PTT) =\< 1.5 x institutional ULN
* Left ventricular ejection fraction (LVEF) \>= institutional lower limit of normal (LLN) by echocardiogram (ECHO) or multigated acquisition scan (MUGA)
* No distinction should be made between liver dysfunction due to metastases and liver dysfunction due to other causes
* Patients with abnormal hepatic function will be eligible and will be grouped according to criteria summarized below:
* Group A: Normal hepatic function
* Bilirubin =\< ULN
* Aspartate aminotransferase (AST) =\< ULN
* Group B: Mild hepatic dysfunction
* B1: bilirubin =\< ULN and AST \> ULN
* B2: ULN \< bilirubin =\< 1.5 x ULN and any AST
* Group C: Moderate hepatic dysfunction
* 1.5 x ULN \< bilirubin =\< 3 x ULN and any AST
* Group D: Severe hepatic dysfunction
* 3 x ULN \< bilirubin =\< 10 x ULN and any AST; hepatic function tests should be repeated within 24 hours prior to starting initial therapy and may result in patients' group assignment being altered if different to registration test results
* Patients with active hemolysis should be excluded. No distinction should be made between liver dysfunction due to metastases and liver dysfunction due to other causes. Hepatic function tests should be repeated within 24 hours prior to starting initial therapy and may result in patients' group assignment being altered if different to registration test results
* Trametinib can cause fetal harm when administered to a pregnant woman; women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry, during the study participation, and for four months after the last dose of the drug; women of child-bearing potential must have a negative serum pregnancy test within 14 days prior to registration and agree to use effective contraception throughout the treatment period and for 4 months after the last dose of study treatment; should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately
* Ability to understand and the willingness to sign a written informed consent document
* Hepatocellular carcinoma (HCC) patients are not required to have histologically or cytologically confirmed malignancy, patients are considered eligible based on tumor markers and/or imaging assessment
* Based on recent data that have shown limited trametinib benefit, patients with the following tumor types will be excluded from the normal and mild cohorts:
* Pancreatic cancer patients
* Colorectal cancer patients
* BRAF V600E melanoma patients who have failed BRAF inhibitors
* Note: Patients with pancreatic cancer, colorectal cancer, and BRAF V600E melanoma patients who have failed BRAF inhibitors are allowed to enroll in the moderate and severe cohorts provided the patients: 1) sign a separate consent form which outlines the extremely limited activity observed in prior studies, and 2) are consented to the study by a protocol-specified designee who is not their longitudinal oncologist
* All patients must have completed any prior chemotherapy, targeted therapy, radiotherapy (unless palliative doses which must be discussed with study principal investigator), surgery, anti-angiogenic therapy or interferon \>= 28 days before study entry
* Eastern Cooperative Oncology Group (ECOG) performance status =\< 2 (Karnofsky \>= 60%)
* Life expectancy of greater than 3 months
* Able to swallow and retain orally-administered medication and does not have any clinically significant gastrointestinal abnormalities that may alter absorption such as malabsorption syndrome or major resection of the stomach or bowels
* All prior treatment-related toxicities must be Common Terminology Criteria for Adverse Events (CTCAE) version 4.0 grade =\< 1 (except alopecia) at the time of enrollment
* Absolute neutrophil count (ANC) \>= 1.2 x 10\^9/L
* Hemoglobin \>= 9 g/dL
* Platelets \>= 75 x 10\^9/L
* Serum creatinine =\< 1.5 mg/dL (=\< 133 umol/L) OR calculated creatinine clearance (Cockcroft-Gault formula) \>= 50 mL/min OR 24-hour urine creatinine clearance \>= 50 mL/min
* Proteinuria =\< +1 on dipstick or =\< 1 gram/24 hours
* Prothrombin time (PT) =\< 1.5 x institutional upper limit of normal (ULN)
* International normalized ratio (INR) =\< 1.5 x institutional ULN
* Partial thromboplastin time (PTT) =\< 1.5 x institutional ULN
* Left ventricular ejection fraction (LVEF) \>= institutional lower limit of normal (LLN) by echocardiogram (ECHO) or multigated acquisition scan (MUGA)
* No distinction should be made between liver dysfunction due to metastases and liver dysfunction due to other causes
* Patients with abnormal hepatic function will be eligible and will be grouped according to criteria summarized below:
* Group A: Normal hepatic function
* Bilirubin =\< ULN
* Aspartate aminotransferase (AST) =\< ULN
* Group B: Mild hepatic dysfunction
* B1: bilirubin =\< ULN and AST \> ULN
* B2: ULN \< bilirubin =\< 1.5 x ULN and any AST
* Group C: Moderate hepatic dysfunction
* 1.5 x ULN \< bilirubin =\< 3 x ULN and any AST
* Group D: Severe hepatic dysfunction
* 3 x ULN \< bilirubin =\< 10 x ULN and any AST; hepatic function tests should be repeated within 24 hours prior to starting initial therapy and may result in patients' group assignment being altered if different to registration test results
* Patients with active hemolysis should be excluded. No distinction should be made between liver dysfunction due to metastases and liver dysfunction due to other causes. Hepatic function tests should be repeated within 24 hours prior to starting initial therapy and may result in patients' group assignment being altered if different to registration test results
* Trametinib can cause fetal harm when administered to a pregnant woman; women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry, during the study participation, and for four months after the last dose of the drug; women of child-bearing potential must have a negative serum pregnancy test within 14 days prior to registration and agree to use effective contraception throughout the treatment period and for 4 months after the last dose of study treatment; should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately
* Ability to understand and the willingness to sign a written informed consent document
Exclusion Criteria
* History of another malignancy
* Exception: patients who have been disease-free for 3 years, or patients with a history of completely resected non-melanoma skin cancer and/or patients with indolent secondary malignancies, are eligible; consult the Cancer Therapy Evaluation Program (CTEP) Medical Monitor if unsure whether second malignancies meet the requirements specified above
* History of interstitial lung disease or pneumonitis
* Any major surgery, extensive radiotherapy, chemotherapy with delayed toxicity, biologic therapy, or immunotherapy within 28 days prior to enrollment and/or daily or weekly chemotherapy without the potential for delayed toxicity within 14 days prior to enrollment
* Use of other investigational drugs within 28 days (or five half-lives, whichever is shorter; with a minimum of 14 days from the last dose) preceding the first dose of trametinib and during the study; patients previously treated with v-raf murine sarcoma (RAF) and/or mitogen-activated protein kinase (MEK) inhibitors are excluded from the study; multikinase antiangiogenic tyrosine kinase inhibitors such as regorafenib, sorafenib, sunitinib, etc. whose primary mechanism of action is not RAF inhibition, are allowed; if there are any questions, please contact study's principal investigator
* Symptomatic or untreated leptomeningeal or brain metastases or spinal cord compression
* Have a known immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs chemically related to trametinib or excipients or to dimethyl sulfoxide (DMSO)
* Current use of a prohibited medication; the following medications or non-drug therapies are prohibited:
* Other anti-cancer therapy while on study treatment; (Note: megestrol \[Megace\] if used as an appetite stimulant is allowed)
* Concurrent treatment with bisphosphonates is permitted; however, treatment must be initiated prior to the first dose of study therapy; prophylactic use of bisphosphonates in patients without bone disease is not permitted, except for the treatment of osteoporosis
* Because the composition, PK, and metabolism of many herbal supplements are unknown, the concurrent use of all herbal supplements is prohibited during the study (including, but not limited to, St. John's wort, kava, ephedra \[ma huang\], ginkgo biloba, dehydroepiandrosterone \[DHEA\], yohimbe, saw palmetto, or ginseng)
* History or current evidence/risk of retinal vein occlusion (RVO)
* History or evidence of cardiovascular risk including any of the following:
* LVEF \< LLN
* A QT interval corrected for heart rate using the Bazett's formula QTcB \>= 480 msec
* History or evidence of current clinically significant uncontrolled arrhythmias (exception: patients with controlled atrial fibrillation for \> 30 days prior to randomization are eligible)
* History of acute coronary syndromes (including myocardial infarction and unstable angina), coronary angioplasty, or stenting within 6 months prior to randomization
* History or evidence of current \>= class II congestive heart failure as defined by the New York Heart Association (NYHA) functional classification system
* Treatment-refractory hypertension defined as a blood pressure of systolic \> 140 mmHg and/or diastolic \> 90 mmHg which cannot be controlled by anti-hypertensive therapy
* Patients with intra-cardiac defibrillators
* Known cardiac metastases
* Active hepatitis B virus (HBV), or hepatitis C virus (HCV) infection (patients with chronic or cleared HBV and HCV infection are eligible)
* Patients with known human immunodeficiency virus (HIV) infection are eligible if not on antiviral agents and cluster of differentiation (CD)4 counts are adequate (\>= 500)
* Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
* Animal reproductive studies have not been conducted with trametinib; therefore, the study drug must not be administered to pregnant women or nursing mothers; women of childbearing potential should be advised to avoid pregnancy and use effective methods of contraception; men with a female partner of childbearing potential must have either had a prior vasectomy or agree to use effective contraception; if a female patient or a female partner of a patient becomes pregnant while the patient receives trametinib, the potential hazard to the fetus should be explained to the patient and partner (as applicable)
* HIV-positive patients on combination antiretroviral therapy are ineligible because of the potential for pharmacokinetic interactions; in addition, these patients are at increased risk of lethal infections when treated with marrow-suppressive therapy; appropriate studies will be undertaken in patients receiving combination antiretroviral therapy when indicated
* Any condition or medical problem in addition to the underlying malignancy and organ dysfunction which the investigator feels would pose unacceptable risk
* Exception: patients who have been disease-free for 3 years, or patients with a history of completely resected non-melanoma skin cancer and/or patients with indolent secondary malignancies, are eligible; consult the Cancer Therapy Evaluation Program (CTEP) Medical Monitor if unsure whether second malignancies meet the requirements specified above
* History of interstitial lung disease or pneumonitis
* Any major surgery, extensive radiotherapy, chemotherapy with delayed toxicity, biologic therapy, or immunotherapy within 28 days prior to enrollment and/or daily or weekly chemotherapy without the potential for delayed toxicity within 14 days prior to enrollment
* Use of other investigational drugs within 28 days (or five half-lives, whichever is shorter; with a minimum of 14 days from the last dose) preceding the first dose of trametinib and during the study; patients previously treated with v-raf murine sarcoma (RAF) and/or mitogen-activated protein kinase (MEK) inhibitors are excluded from the study; multikinase antiangiogenic tyrosine kinase inhibitors such as regorafenib, sorafenib, sunitinib, etc. whose primary mechanism of action is not RAF inhibition, are allowed; if there are any questions, please contact study's principal investigator
* Symptomatic or untreated leptomeningeal or brain metastases or spinal cord compression
* Have a known immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs chemically related to trametinib or excipients or to dimethyl sulfoxide (DMSO)
* Current use of a prohibited medication; the following medications or non-drug therapies are prohibited:
* Other anti-cancer therapy while on study treatment; (Note: megestrol \[Megace\] if used as an appetite stimulant is allowed)
* Concurrent treatment with bisphosphonates is permitted; however, treatment must be initiated prior to the first dose of study therapy; prophylactic use of bisphosphonates in patients without bone disease is not permitted, except for the treatment of osteoporosis
* Because the composition, PK, and metabolism of many herbal supplements are unknown, the concurrent use of all herbal supplements is prohibited during the study (including, but not limited to, St. John's wort, kava, ephedra \[ma huang\], ginkgo biloba, dehydroepiandrosterone \[DHEA\], yohimbe, saw palmetto, or ginseng)
* History or current evidence/risk of retinal vein occlusion (RVO)
* History or evidence of cardiovascular risk including any of the following:
* LVEF \< LLN
* A QT interval corrected for heart rate using the Bazett's formula QTcB \>= 480 msec
* History or evidence of current clinically significant uncontrolled arrhythmias (exception: patients with controlled atrial fibrillation for \> 30 days prior to randomization are eligible)
* History of acute coronary syndromes (including myocardial infarction and unstable angina), coronary angioplasty, or stenting within 6 months prior to randomization
* History or evidence of current \>= class II congestive heart failure as defined by the New York Heart Association (NYHA) functional classification system
* Treatment-refractory hypertension defined as a blood pressure of systolic \> 140 mmHg and/or diastolic \> 90 mmHg which cannot be controlled by anti-hypertensive therapy
* Patients with intra-cardiac defibrillators
* Known cardiac metastases
* Active hepatitis B virus (HBV), or hepatitis C virus (HCV) infection (patients with chronic or cleared HBV and HCV infection are eligible)
* Patients with known human immunodeficiency virus (HIV) infection are eligible if not on antiviral agents and cluster of differentiation (CD)4 counts are adequate (\>= 500)
* Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
* Animal reproductive studies have not been conducted with trametinib; therefore, the study drug must not be administered to pregnant women or nursing mothers; women of childbearing potential should be advised to avoid pregnancy and use effective methods of contraception; men with a female partner of childbearing potential must have either had a prior vasectomy or agree to use effective contraception; if a female patient or a female partner of a patient becomes pregnant while the patient receives trametinib, the potential hazard to the fetus should be explained to the patient and partner (as applicable)
* HIV-positive patients on combination antiretroviral therapy are ineligible because of the potential for pharmacokinetic interactions; in addition, these patients are at increased risk of lethal infections when treated with marrow-suppressive therapy; appropriate studies will be undertaken in patients receiving combination antiretroviral therapy when indicated
* Any condition or medical problem in addition to the underlying malignancy and organ dysfunction which the investigator feels would pose unacceptable risk
Minimum Eligible Age
18 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Cancer Institute (NCI)
NIH
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Responsibility Role
SPONSOR
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Lillian L Siu
Role: PRINCIPAL_INVESTIGATOR
University Health Network Princess Margaret Cancer Center LAO
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of California Davis Comprehensive Cancer Center
Sacramento, California, United States
Site Status
Moffitt Cancer Center
Tampa, Florida, United States
Site Status
University of Chicago Comprehensive Cancer Center
Chicago, Illinois, United States
Site Status
Wayne State University/Karmanos Cancer Institute
Detroit, Michigan, United States
Site Status
Washington University School of Medicine
St Louis, Missouri, United States
Site Status
Rutgers Cancer Institute of New Jersey
New Brunswick, New Jersey, United States
Site Status
Ohio State University Comprehensive Cancer Center
Columbus, Ohio, United States
Site Status
M D Anderson Cancer Center
Houston, Texas, United States
Site Status
BCCA-Vancouver Cancer Centre
Vancouver, British Columbia, Canada
Site Status
Juravinski Cancer Centre at Hamilton Health Sciences
Hamilton, Ontario, Canada
Site Status
University Health Network-Princess Margaret Hospital
Toronto, Ontario, Canada
Site Status
Countries
Review the countries where the study has at least one active or historical site.
United States
Canada
References
Explore related publications, articles, or registry entries linked to this study.
Voon PJ, Chen EX, Chen HX, Lockhart AC, Sahebjam S, Kelly K, Vaishampayan UN, Subbiah V, Razak AR, Renouf DJ, Hotte SJ, Singh A, Bedard PL, Hansen AR, Ivy SP, Wang L, Stayner LA, Siu LL, Spreafico A. Phase I pharmacokinetic study of single agent trametinib in patients with advanced cancer and hepatic dysfunction. J Exp Clin Cancer Res. 2022 Feb 7;41(1):51. doi: 10.1186/s13046-021-02236-7.
Reference Type
DERIVED
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
NCI-2014-00416
Identifier Type: REGISTRY
Identifier Source: secondary_id
NCI 9591
Identifier Type: -
Identifier Source: secondary_id
9591/PJC-015
Identifier Type: -
Identifier Source: secondary_id
PJC-015
Identifier Type: -
Identifier Source: secondary_id
9591
Identifier Type: OTHER
Identifier Source: secondary_id
9591
Identifier Type: OTHER
Identifier Source: secondary_id
NCI-2014-00416
Identifier Type: -
Identifier Source: org_study_id
NCT02007382
Identifier Type: -
Identifier Source: nct_alias
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
A Study to Compare the Blood Levels and Safety of Tazemetostat in Participants With Advanced Cancer and Moderate/Severe Liver Impairment to Participants With Advanced Cancer and Normal Liver Function
NCT04241835
RECRUITING
PHASE1
Pharmacokinetics of Tivantinib in Subjects With Advanced Solid Tumors and Hepatic Impairment
NCT02150733
COMPLETED
PHASE1
Trebananib And Temsirolimus in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery
NCT01548482
COMPLETED
PHASE1
Selumetinib in Treating Patients With Locally Advanced or Metastatic Liver Cancer
NCT00604721
COMPLETED
PHASE2
Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 and Temsirolimus in Treating Patients With Advanced Solid Tumors
NCT01198184
COMPLETED
PHASE1
A Phase II Study of Single Tremelimumab With Regular Interval Durvalumab Plus Gemcitabine and Cisplatin in Locally Advanced Unresectable/Metastatic Combined Hepatocellular-cholangiocarcinoma
NCT06855225
NOT_YET_RECRUITING
PHASE2
Testing Cabozantinib in Patients With Advanced Pancreatic Neuroendocrine and Carcinoid Tumors
NCT03375320
ACTIVE_NOT_RECRUITING
PHASE3
Testing the Addition of the Anti-cancer Drug, Tazemetostat, to the Usual Treatment (Dabrafenib and Trametinib) for Metastatic Melanoma That Has Progressed on the Usual Treatment
NCT04557956
ACTIVE_NOT_RECRUITING
PHASE1/PHASE2
Trametinib in Treating Patients With Advanced Melanoma With BRAF Non-V600 Mutations
NCT02296112
COMPLETED
PHASE2
Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations
NCT04550494
RECRUITING
PHASE2
Continuous 24h Intravenous Infusion of Mithramycin, an Inhibitor of Cancer Stem Cell Signaling, in People With Primary Thoracic Malignancies or Carcinomas, Sarcomas or Germ Cell Neoplasms With Pleuropulmonary Metastases
NCT02859415
TERMINATED
PHASE1/PHASE2
BC3402 w/ Tremelimumab + Durvalumab (STRIDE) in Hepatocellular Carcinoma
NCT06608940
NOT_YET_RECRUITING
PHASE1/PHASE2
A Study to Test the Addition of the Drug Cabozantinib to Chemotherapy in Patients With Newly Diagnosed Osteosarcoma
NCT05691478
RECRUITING
PHASE2/PHASE3
Uprosertib, Dabrafenib, and Trametinib in Treating Patients With Stage IIIC-IV Cancer
NCT01902173
COMPLETED
PHASE1/PHASE2
Testing Trametinib as a Potential Targeted Treatment in Cancers With GNAQ or GNA11 Genetic Changes (MATCH-Subprotocol S2)
NCT04439357
ACTIVE_NOT_RECRUITING
PHASE2
Chemotherapy in Treating Patients With Refractory Advanced Solid Tumors or Hematologic Cancer
NCT00004065
COMPLETED
PHASE1
Phase 1 Combination Study of MM-151 With MM-121, MM-141, or Trametinib
NCT02538627
TERMINATED
PHASE1
Efficacy and Safety of Momelotinib Combined With Trametinib in Adults With Metastatic KRAS-mutated Non-Small Cell Lung Cancer (NSCLC) Who Have Failed Platinum-Based Chemotherapy Preceded by a Dose-finding Lead-in Phase
NCT02258607
TERMINATED
PHASE1
Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma
NCT01008917
COMPLETED
PHASE1
A Study of Temsirolimus Plus Capecitabine in Patients With Advanced Cancer
NCT01050985
COMPLETED
PHASE1
Testing Trametinib as a Potential Targeted Treatment in Cancers With NF1 Genetic Changes (MATCH-Subprotocol S1)
NCT04439318
ACTIVE_NOT_RECRUITING
PHASE2
A Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Anti-Cancer Activity of Trametinib in Combination With Palbociclib in Subjects With Solid Tumors
NCT02065063
COMPLETED
PHASE1
S0809: Capecitabine, Gemcitabine, and RT in Patients w/Cholangiocarcinoma of the Gallbladder or Bile Duct
NCT00789958
COMPLETED
PHASE2
Trametinib With or Without GSK2141795 in Treating Patients With Metastatic Uveal Melanoma
NCT01979523
ACTIVE_NOT_RECRUITING
PHASE2
Sorafenib in Treating Patients With Metastatic, Locally Advanced, or Recurrent Sarcoma
NCT00245102
COMPLETED
PHASE2